Key Details
Price
$78.91Annual Revenue
$493.63 MAnnual EPS
-$0.03Annual ROE
-0.37%Beta
0.51Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 28, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Inari (NASDAQ: NARI) for possible breaches of fiduciary duty and other violations of law in its transaction with the Stryker. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Inari stockholders will receive $80 per share, representing a total fully diluted equity value of approximatel.
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
FAQ
- What is the primary business of Inari Medical?
- What is the ticker symbol for Inari Medical?
- Does Inari Medical pay dividends?
- What sector is Inari Medical in?
- What industry is Inari Medical in?
- What country is Inari Medical based in?
- When did Inari Medical go public?
- Is Inari Medical in the S&P 500?
- Is Inari Medical in the NASDAQ 100?
- Is Inari Medical in the Dow Jones?
- When was Inari Medical's last earnings report?
- When does Inari Medical report earnings?
- Should I buy Inari Medical stock now?